Numab Therapeutics AG with headquarters in Horgen in the Swiss canton of Zurich is selling its wholly owned subsidiary Yellow Jersey Therapeutics to the North American pharmaceutical giant Johnson & Johnson, which is located in the US state of New Jersey. According to a press release, the agreement that has been reached stipulates a purchase price of 1.25 billion US dollars for the subsidiary that was established in 2024. The transaction is expected to take place in the second half of 2024.
This includes all assets linked to NM26, a biospecific antibody. It is designed to treat atopic dermatitis in the form of eczema or neurodermatitis and is about to start phase 2 clinical trials.
The antibody targets certain type I and II receptors and thus the characteristic features of the pathophysiology of this disease. It was discovered and developed using Numab’s MATCH technology platform. This aims to create a new range of multi-specific antibody drug candidates.
Numab’s founder and CEO David Urech commented: “This transaction validates the power of our discovery and engineering platform and its potential to bring multiple novel multi-specific antibodies to large, underserved patient populations.” He went on to add: “Our partnering strategy, engaging biopharma partners such as Kaken, Eisai, Boehringer Ingelheim and Ono from early on, has been instrumental in realizing the value of our platform and will continue to be key to advancing our potentially transformative immunology and oncology platforms.” ce/mm
Related news
Meet with an expansion expert
Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center? Give us a call or drop us a line.